Comparative Advantages of National Pharmaceutical Industries through the Prism of New Indicators

Keywords: comparative advantages, specialization, high tech goods, high tech industries, pharmaceutical industry, exports, value added, transnational corporations.


Specific ways of the emergence of new actors in the global market of pharmaceutical goods is investigated, with substantiating the role of transnational corporations (TNC), their investment and technologies in establishing pharmaceutical industries in developing countries. The cases of Puerto Rico and Ireland are taken in order to demonstrate the background for expansion of manufacturing of medicines and medical products and analyze the tendencies in their export capacity building. The factors making pharmaceutical TNC transfer production facilities to India and China are substantiated and implications of this process are highlighted. It is revealed that due to the production internationalization, countries that had been net importers of pharmaceuticals just several decades ago have joined the group of key suppliers to external markets. Because American and European TNC are leading in the pharmaceutical industry by R&D expenditure, they are the principal holders of advanced technologies in the industry. It follows that manufacturing of medicines and medical products in most part of countries either directly or indirectly depend on innovative products of TNC and their technology transfer via various channels (both licensing and imports of components, active pharmaceutical ingredients in particular). It is shown that with the emergence of new market actors coming from developing countries, traditional approaches to determining comparative advantages of counties in the global trade need to be improved. The cases of countries that are recipients of foreign technologies, on which territories powerful high tech pharmaceutical production facilities with high shares of intermediate consumption and heavy export supplies are located due to TNC investment or local public-private capital, give evidence that the classical RCA indicator allows to measure visible comparative advantages in the trade in goods rather than revealed ones. It is proposed that analyses of advantages at country level should include the indicator of high tech goods supplies, to provide for a more accurate description of the innovation component in advanced industries. A new approach to the assessment of comparative advantages of high tech pharmaceutical manufacturing is proposed and tested, which is based on the principle of specialization and use of the ratio of Comparative Advantage in Value Added Activity (CAVA) in particular. It is revealed that the pharmaceutical industry of Ireland, Jordan, Singapore, India or Columbia, with reliance on foreign investment and technologies, could gain advantages in value added creation and dominate the national economies. It is shown that Ukraine is enhancing the advantages in value added creation in the pharmaceutical industry; is it substantiated that due to low R&D and innovation performance and heavy dependence on imported components, capacity building of this industry and its current advantages result from global tendencies and global market conjunctures rather than from the implementation of the national science & technology priorities. According to the author’s recommendation, the proposed approach to determining comparative advantages in value added creation should be used for the assessment of other high tech industries, apart from the pharmaceutical industry, and that is should be supplemented by statistical tools for analysis of foreign trade in finished and intermediate high tech goods.


Download data is not yet available.


Dependency of the EU pharmaceutical industry on active pharmaceutical ingredients and chemical raw materials imported from third countries. (2020). European Commission. Pharmaceutical Committee. Retrieved from

Brunsden, J., & Peel, M. (2020). Covid-19 exposes EU’s reliance on drug imports. Retrieved from

Exposing the Risks of America’s Dependence on China for Medicine. Testimony of Rosemary Gibson. (2020). Retrieved from

S. 3537 – Protecting Our Pharmaceutical Supply Chain from China Act of 2020 (2020). 116th Congress. Retrieved from

Valverde, J. L., & Pisani, E. (Eds.). (2016). The Globalisation of the Pharmaceutical Industry. Pharmaceuticals policy and law. Vol. 18. Retrieved from

Pharmaceutical Industry. Tax Benefits of Operating in Puerto Rico. (1992). Briefing Report to the Chairman, Special Committee on Ageing, U.S. Senate. Retrieved from

An Act to reform the tax lows of the United States. (1976). Public Low 94–455 — Oct. 4, 1976. [H.R. 10612]. Retrieved from

Tax Policy Puerto Rico and the Section 936 Tax Credit. (1993). Report to the Chairman, Committee on Finance, U.S. Senate. Retrieved from

The Operatioll and Effect of the Possessions Corporation System of Taxation. Third Annual Report. (1980). Retrieved from

Neumann, A. L. (1981). U.S. Pharmaceutical Giants Move to Puerto Rico for Tax Breaks. The Multinational Monitor, 2, 10. Retrieved from

Top 20 Pharma Companies in Puerto Rico. (2019). Retrieved from

Securing the Future for Puerto Rico: Restoring the Island’s Robust Medical Product Manufacturing Sector Retrieved from

Selected Statistics on Puerto Rico’s External Trade, 2019. (2020). Retrieved from

Canadian total exports. (2020). Report – Trade Data Online. Retrieved from

Cadanet, A. (2019). Puerto Rico, un paraíso para las ‘farmas’: el país engloba un 3% de la producción mundial. Retrieved from

Feliciano, Z. M., & Green, A. (2017). US Multinationals in Puerto Rico and the Repeal of Section 936 Tax Exemption for U.S. Corporations. NBER Working Paper, 23681 Retrieved from

Economic Incentives for the Development of Puerto Rico Act (Act No. 73 of May 28, 2008). (2013). PRIDCO. Retrieved from

Corporation tax in the Republic of Ireland. Retrieved March 30, 2020 from

Global FDI flows flat in 2019. Moderate increase expected in 2020. (2020). UNCTAD Global Investment Trends Monitor, Is. 33. Retrieved from

Irish Industrial Production by Sector. (2020). Retrieved from

Pathway to Global Product Safety and Quality. (2012). U.S. Food and Drug Administration, Special Report. Retrieved from

Bumpas, J., & Betsch, E. (2009). Exploratory Study on Active Pharmaceutical Ingredient Manufacturing for Essential Medicines. Retrieved from

Pharmaceutical Residues in Freshwater: Hazards and Policy Responses. (2019). Part 3. Emerging policy instruments for the control of pharmaceuticals in water. Retrieved from

Securing the U.S. drug supply chain: oversight of FDA’s foreign inspection program. Testimony of Janet Woodcock. (2019). Retrieved from

EvaluatePharma® World Preview 2020, Outlook to 2026. Executive Summary. (2020). Retrieved from

Salikhova, O. B. (2012). Novi pidkhody do vyznachennia mizhnarodnykh porivnialnykh perevah [New approaches to determining international comparative advantages]. Ekonomika ta prohnozuvannia – Economу and Forecasting, 1, 101–120. Retrieved from [in Ukrainian].

Extra-EU exports of basic pharmaceutical products and preparations, 2019. Eurostat. Retrieved March 30, 2020 from,_2019.png&oldid=475846

Revealed comparative advantage. United Nations Conference on Trade and Development. Retrieved from

Salikhova, O. B., & Honcharenko, D. O. (2020). Endohenizatsiia ekonomichnoho rozvytku cherez rozbudovu vysokotekhnolohichnykh farmatsevtychnykh vyrobnytstv: dosvid Yevropy, uroky dlia Ukrainy [Endogenization of Economic Development through the Development of High-Tech Pharmaceutical Industries: Europe’s Experience, Lessons for Ukraine]. Biznes Inform – Business Inform, 2, 49–56. Retrieved from [in Ukrainian].

Salikhova, O. B., & Honcharenko, D. O. (2020). Polityka endohennoho rozvytku farmatsevtyky v Kytai: uroky dlia Ukrainy [Policy of Endogenous Development of Pharmaceuticals in China: Lessons for Ukraine]. Ekonomika ta prohnozuvannia – Economу and Forecasting, 2, 139–157 [in Ukrainian].

Eurostat indicators on High-tech industry and Knowledge – intensive services. Annex 5. High-tech aggregations by SITC Rev. 4. European Commission. Retrieved January 30, 2020 from

Annual detailed enterprise statistics for industry (NACE Rev. 2, B-E). (2015). European Commission. Retrieved from

High-tech trade by high-tech group of products in million euro (from 2007, SITC Rev. 4). Eurostat. Retrieved April 29, 2019 from

Science and Engineering Indicators 2020. (2020). National Science Foundation. Retrieved from

World Development Indicators. Retrieved from

Honcharenko, D. O. (2020). New Approaches to the Assessment of Foreign Trade in High-Tech Pharmaceuticals. Statystyka Ukrainy – Statistics of Ukraine, 1, 35–41. Doi: 10.31767/su. 1(88)2020.01.04.

Salikhova, O. B., & Honcharenko, D. O. (2020). Kontseptualni zasady stratehii rozvytku vysokotekhnolohichnoi industrii likarskykh zasobiv ta medychnykh vyrobiv v Ukraini do 2030 r. [The Conceptual Foundations of the Strategy of Development of the High-Tech Industry of Pharmaceuticals and Medical Products in Ukraine till 2030]. Biznes Inform – Business Inform, 7, 28–35. Retrieved from [in Ukrainian].

Al Faisal, Md. Ab. (2019). Pharmaceutical Industry of Bangladesh. The multi-billion Dollar Industry. (3d ed.). Retrieved from

Pro okhoronu prav na vynakhody i korysni modeli: Zakon Ukrainy vid December 15.12.1993 r. № 3687-XII, stanom na 05.12.2012 r. [On protection of rights for inventions and utility models: Law of Ukraine of 15.12.1993 № 3687-XII, as of 05.12.2012]. Retrieved March 30, 2020 from [in Ukrainian].

Pro likarski zasoby: Zakon Ukrainy vid 04.04.1996 r. № 123/96-ВР, stanom na 18.03.2020 р. [On Medicines. Law of Ukraine of April 4, 1996 № 123/96-VR as of March 18, 2020]. Retrieved March 30, 2020 from [in Ukrainian].

Abstract views: 315
PDF Downloads: 303
How to Cite
Salikhova, O. B. (2020). Comparative Advantages of National Pharmaceutical Industries through the Prism of New Indicators . Statistics of Ukraine, 8990(2-3), 48-58.